BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use

 
• By Ian Schofield
  
SC1606_Funding_1200
NICE is moving products from the Cancer Drugs Fund to NHS Commissioning

More from Health Technology Assessment

More from Market Access